MaxCyte Highlights Innovations in Scalable, High-Throughput Transient Transfection for Streamlining Antibody Development and Production at PepTalk 2013, Booth #307

GAITHERSBURG, Md. -- (BUSINESS WIRE) -- MaxCyte, Inc., the pioneer in scalable, high performance transient transfection systems, is hosting a series of events at Cambridge Healthtech Institute’s 12^th Annual PepTalk to be held January 21-25 in Palm Springs, CA. MaxCyte will present antibody development case studies in a scientific talk, detail breakthrough data in a technical poster, and schedule one-on-one discussions in Booth #307 to demonstrate how the MaxCyte STX® Scalable Transfection System and MaxCyte VLX® Large Scale Transfection System can improve the speed, biologic relevance, and process design for protein and antibody screening and manufacturing.

“MaxCyte STX and VLX users achieve gram-scale antibody and protein expression in an appropriate biomanufacturing host cell line with a simple 20-30 minute transfection run. This rapid, high titer production enables detailed characterization and screening of biotherapeutic candidates from the earliest stages of development, without the time, expense, and corresponding limitations of generating stable cells lines,” says Dr. Karen Donato, Executive Vice President of Global Business Development & Marketing at MaxCyte. “The MaxCyte platform also has unique process features that can improve downstream operations and reduce production and purification requirements.”

Dr. James Brady, Director of Technical Applications at MaxCyte, will present case studies of antibody expression data using flow electroporation in a scientific talk entitled “Fully Scalable Transient Gene Expression in CHO Cells for Gram-Scale Antibody Production” on Wednesday, January 23, 2013, at 3:05 PM in the session “Fine-Tuning Expression in CHO: Improving Yields and Engineering Overexpression”. MaxCyte will also present a scientific poster entitled “Streamlining Antibody Development Using Large Scale, CHO Transient Gene Expression (TGE) Followed by Rapid Production of CHO Stable Pools” with data demonstrating the utility of the MaxCyte platform at multiple steps in antibody development. MaxCyte scientists will be available during the PEPTALK Conference at Booth #307 for further technical discussions.

“Biopharmaceutical companies have expressed a significant need to improve the speed, reliability, and predictability in their antibody discovery and development programs,” says Douglas Doerfler, President and CEO of MaxCyte. “The MaxCyte flow electroporation platform helps companies meet these goals and choose the best candidates to move forward in their pipelines.”

About MaxCyte

MaxCyte specializes in cell modification technologies to enable the discovery, development, manufacturing, and delivery of innovative therapeutic products. Drawing on its cell therapy expertise, MaxCyte designed a portfolio of products including the MaxCyte STX^® Scalable Transfection System and the MaxCyte^® VLX™ Large Scale Transfection System, ideal tools for use in small molecule drug discovery screening, protein drug development, recombinant vaccine production/manufacturing, and cell therapy commercialization. These products provide for the rapid development and consistent production of billions of (co)transfected primary cells, stem cells, and cell lines with Seamless Scalability™ from the bench to commercial scale.

For more information, http://www.maxcyte.com